[The status of plasma level determination of anticonvulsants]. 1989

G Krämer
Neurologische Universitätsklinik Mainz.

Based on pharmacologic-pharmacokinetic data a critical synopsis of the role of anticonvulsant plasma level determinations in the treatment of epilepsy is given. The analytical methods themselves and the validity of the so called therapeutic range are evaluated in general as well as for the particular antiepileptic drugs. Whereas plasma levels of phenytoin play an important role in therapeutic management they are without major relevance in the therapy with clonazepam and other benzodiazepines. Determinations of anticonvulsant concentrations can be of help in certain circumstances of therapeutic decisions, but uncritical usage as a routine method has to be discouraged. So far, prospective studies were not able to proof a general advantage of this method in the management of epileptic patients.

UI MeSH Term Description Entries
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D004827 Epilepsy A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313) Aura,Awakening Epilepsy,Seizure Disorder,Epilepsy, Cryptogenic,Auras,Cryptogenic Epilepsies,Cryptogenic Epilepsy,Epilepsies,Epilepsies, Cryptogenic,Epilepsy, Awakening,Seizure Disorders
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000927 Anticonvulsants Drugs used to prevent SEIZURES or reduce their severity. Anticonvulsant,Anticonvulsant Drug,Anticonvulsive Agent,Anticonvulsive Drug,Antiepileptic,Antiepileptic Agent,Antiepileptic Agents,Antiepileptic Drug,Anticonvulsant Drugs,Anticonvulsive Agents,Anticonvulsive Drugs,Antiepileptic Drugs,Antiepileptics,Agent, Anticonvulsive,Agent, Antiepileptic,Agents, Anticonvulsive,Agents, Antiepileptic,Drug, Anticonvulsant,Drug, Anticonvulsive,Drug, Antiepileptic,Drugs, Anticonvulsant,Drugs, Anticonvulsive,Drugs, Antiepileptic

Related Publications

G Krämer
October 1987, Medizinische Klinik (Munich, Germany : 1983),
G Krämer
January 1976, Clinical pharmacokinetics,
G Krämer
December 1973, Nederlands tijdschrift voor geneeskunde,
G Krämer
June 1973, Australian and New Zealand journal of medicine,
G Krämer
May 1994, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie,
G Krämer
January 1988, Voprosy meditsinskoi khimii,
Copied contents to your clipboard!